Advanced Solutions
for Advanced Pathology
SV40 (MRQ-4)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45335 IMPATH SV-40 RTU M (MRQ-4)
50 Tests
44391 SV-40 RTU M (MRQ-4)
7 ml Ready To Use
44801 SV-40 0,1 M (MRQ-4)
100 µl liquid Concentrated
44802 SV-40 1 M (MRQ-4)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
SV-40 infected tissue
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2a
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
SV40, Simian Virus 40, is a polyomavirus that is found in both monkeys and humans. Like other polyomaviruses, SV40 is a DNA virus that has
the potential to cause tumors. SV40 is believed to suppress the transcriptional properties of tumor-suppressing p53 in humans through the SV40
large T-antigen and SV40 small T-antigen. It is generally assumed that large T-antigen is the major protein involved in neoplastic processes and
the large T-antigen predominantly exerts its effect through deregulation of tumor suppressor p53, which is responsible for initiating regulated cell
death (“apoptosis”), or cell cycle arrest when a cell is damaged. A mutated p53 gene may contribute to uncontrolled cellular proliferation, leading
to a tumor. The hypothesis that SV40 might cause cancer in humans has been a particularly controversial area of research. Some research
has suggested that SV40 is associated with brain tumors, bone cancers, non-Hodgkin lymphoma, and malignant mesothelioma. Anti-SV40
recognizes the large T-antigen of SV40.
Reference
1. Gurney EG, et al. J Virl. 1980; 34:752-763.
2. Huang H, et al. Brain Pathol. 1999; 9:33-42.
3. Arrington AS, Butel JS. Molecular and Clinical Perspectives. 2001; 461-489.
4. Pershouse M, et al. Inhal Toxicol. 2006 Nov; 18(12):995-1000.
5. Kroczynska B, et al. PNAS. 2006 Sep 19; 103(38):14128-33.
6. Poulin DL, DeCaprio JA. J Clini Oncology. 2006; 24:4356-65.
221
